Colorectal Cancer
Evidence-based overview of silymarin and milk thistle in colorectal cancer, including chemotherapy synergy and PD-L1 findings
Silymarin in Colorectal Cancer
Overview
Silymarin, a polyphenolic flavonoid complex extracted from milk thistle (Silybum marianum), has demonstrated significant anticancer activity in colorectal cancer preclinical models. Research indicates its potential to inhibit tumour proliferation, induce apoptosis, modulate key signalling pathways such as Wnt/β-catenin and PI3K/AKT/mTOR, reduce inflammatory markers, enhance immune responses, and synergise with conventional chemotherapy. Studies investigate both standalone effects and interactions with chemotherapeutic agents, positioning silymarin as a promising adjunctive agent worthy of further clinical investigation.
How Silymarin May Work in Colorectal Cancer
Silymarin exerts its effects through multiple interconnected mechanisms. Key pathways identified in laboratory studies include:
Suppressing proliferation and inducing apoptosis via modulation of the Bax/Bcl-2 ratio—increasing pro-apoptotic Bax and decreasing anti-apoptotic Bcl-2
Inhibiting the Wnt/β-catenin pathway by inducing GSK3β-dependent proteasomal degradation of β-catenin and Axin-dependent downregulation of TCF4, thereby reducing nuclear β-catenin levels and transcriptional activity of target genes (e.g., c-Myc, cyclin D1)
Altering key cancer pathways such as PI3K/AKT/mTOR and NF-κB signalling, which are central to tumour survival, growth, and therapy resistance
Inducing G1 cell cycle arrest through inhibition of cyclin-dependent kinase activity and upregulation of cyclin-dependent kinase inhibitors p21^CIP1^ and p27^KIP1^
Promoting apoptosis via extrinsic (death receptor) and intrinsic (mitochondrial) pathways, evidenced by increased calreticulin exposure, ATP secretion, HMGB1 secretion (markers of immunogenic cell death), and caspase activation
Exhibiting cytotoxic and apoptotic potency, particularly when formulated in nanoparticle delivery systems (e.g., tin(IV) oxide, chitosan) to overcome bioavailability limitations
Inhibiting the secretion of pro-angiogenic factors from tumour cells, thereby reducing vascular endothelial growth factor (VEGF) and interfering with tumour blood supply
Demonstrating antioxidant and anti-inflammatory properties that may protect normal tissues while sensitising tumour cells to oxidative stress
Suppressing mitogenic and cell survival signalling pathways, including epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2)
Modulating the tumour immune microenvironment by increasing inflammatory CD8+ T cell responses in tumour-bearing mice
Targeting cancer-associated fibroblasts (CAFs) by reducing proliferation, colony formation, and migration, and decreasing key fibroblast activation markers such as α-SMA and POSTN
Findings by Colorectal Cancer Models
Silymarin and its major active component silibinin have demonstrated activity across various colorectal cancer cell lines and murine models:
Human Colorectal Cancer Cell Lines
In CT-26 (murine colon carcinoma) and Caco-2 (human epithelial colorectal adenocarcinoma) cells, silymarin significantly reduced cell viability and proliferation in a dose-dependent manner, with IC₅₀ values ranging from approximately 2.3 to 85.2 mg/mL depending on the assay and cell line
Silymarin treatment increased markers of immunogenic cell death (calreticulin exposure, ATP secretion, HMGB1 secretion) in both CT-26 and Caco-2 cells
In SW480 cells (harbouring mutant APC gene), silibinin significantly decreased nuclear and cytoplasmic levels of beta-catenin, downregulated beta-catenin target genes (c-Myc, cyclin D1), inhibited CDK8 expression, and suppressed TCF-4 transcriptional activity; no significant effects were observed in HCT116 cells (wildtype APC), indicating selective action on beta-catenin pathway in mutant APC backgrounds
In HT-29, LoVo, and SW480 cells, silibinin decreased colonosphere formation (a stem cell characteristic) and reduced mRNA/protein levels of cancer stem cell regulatory molecules (LGR5, ASCL2, CD44, CD133, OCT4, NANOG, MSI-1, BMI-1, HES-1)
In CaCo-2 cells, silymarin-loaded tin(IV) nanoparticles exhibited enhanced bioavailability and antiproliferative effects, reducing cell viability over 6–24 hours of treatment
Silymarin has been shown to downregulate gene products involved in tumour cell proliferation (EGFR, COX-2) and invasion (matrix metalloproteinases)
Murine Models of Colorectal Cancer
In CT-26 tumour-bearing mice, silymarin treatment decreased tumour size and increased survival of colorectal cancer cells compared to controls, with effects comparable to doxorubicin in some studies
Silymarin reduced the expression of genes related to cell proliferation (β-catenin, cyclin D1) and anti-apoptotic factors (Bcl-2) while increasing pro-apoptotic Bax in tumour tissues
The number of CD8+ cytotoxic T lymphocytes (CTLs) increased in the spleen of silymarin-treated mice compared to untreated mice, indicating enhanced anti-tumour immune response
Histological analysis revealed decreased tumour size and improved survival in silymarin-treated tumour-bearing mice
In an AOM/DSS-induced colorectal cancer model, silibinin effectively reduced POSTN and α-SMA protein levels in cancer-associated fibroblasts (CAFs) and inhibited CAF proliferation, colony formation, and migration
Silymarin supplementation significantly mitigated elevated inflammatory cytokines (TNF-α, IL-6), liver function enzyme levels, and hyperlipidemia in carcinogen-induced models
Treatment regimens significantly reduced serum LDH levels and enhanced antioxidant activities (SOD, GPx) compared to carcinogen-exposed controls
Silymarin ameliorated carcinogen-induced polyp multiplicity, adenoma formation, dysplastic changes, and lymphocytic aggregation in preclinical models
Cancer Stem Cell Targeting
Cancer stem cells are a subpopulation of cells believed to drive recurrence and treatment resistance in colorectal cancer. They are identified by surface markers including CD44^+^EpCAM^high^ or ALDH^+^ expression.
Laboratory and in vivo studies have shown that silymarin, particularly silibinin, targets colorectal cancer stem cells:
Silibinin strongly decreases the percentage of colonosphere formation (a stem cell characteristic) in CRC cell lines (HT-29, LoVo, SW480)
This effect on cancer stem cells is mediated via blocking of interleukin (IL)-4/6 signalling, leading to decreased IL-4/6 induced activation of STAT-3 and NF-κB transcriptional activity
Silibinin significantly reduces mRNA and protein levels of cancer stem cell regulatory molecules and markers (LGR5, ASCL2, CD44, CD133, OCT4, NANOG, MSI-1, BMI-1, HES-1)
Symmetric self-renewal of cancer stem cells is decreased, while asymmetric self-renewal is increased, shifting cell division towards symmetric proliferation and generating more differentiated clones
Silibinin significantly reduces the booster signals of macrophages towards cancer stem cells, resulting in decreased colonosphere numbers under both normoxic and hypoxic conditions
In vivo studies show that silibinin treatment reduces the tumorigenic potential of cancer stem cells (CD44^+^EpCAM^high^ CRC cells) and inhibits cancer stem cell self-renewal in serial transplantation studies
After treatment, silibinin inhibits both cancer stem cell and bulk daughter cell proliferation, and transforms/differentiates the CD44^+^ population into a CD44^- phenotype
Chemosensitisation: Doxorubicin and Other Combinations
Silymarin demonstrates notable synergy with doxorubicin and other chemotherapeutic agents:
Silymarin suppresses proliferation and PD-L1 expression in colorectal cancer cells almost as much as doxorubicin, suggesting comparable anti-proliferative efficacy
In combination with doxorubicin, silymarin enhances apoptotic effects while reducing oxidative stress in normal hepatocytes
Silymarin sensitises tumours to chemotherapeutic agents through down-regulation of the multidrug resistance protein (MDR1/P-glycoprotein) and other mechanisms
Dietary silymarin supplementation with chemotherapeutic agents significantly mitigated elevated inflammatory cytokines, liver function enzyme levels, and hyperlipidemia
Significant upregulation of BAX and downregulation of Bcl-2 were observed in combination treatments, enhancing pro-apoptotic signalling
Treatment regimens ameliorated carcinogen-induced polyp multiplicity, adenoma formation, dysplastic changes, and lymphocytic aggregation when combined with chemotherapy
Silymarin alone and in combination with irinotecan (SMN-IRI) produced a greater reduction in TNF-α levels than capecitabine-based regimens (SMN-CAP), while effects on CRP levels varied by regimen
Silymarin enhances chemotherapy efficacy and reduces carcinogen- and chemotherapy-induced hepatotoxicity through antioxidant and anti-inflammatory actions
Selenium combined with silybin has been shown to enhance therapeutic effects in colorectal cancer models
Radiotherapy Support
Direct radiotherapy studies for silymarin in colorectal cancer are limited, but the mechanistic rationale supports investigation:
Silymarin’s antioxidant capacity may protect normal tissue from radiation-induced oxidative damage
By inhibiting NF-κB and reducing inflammatory cytokines, silymarin could mitigate radiotherapy-induced inflammation
Its anti-angiogenic effects may interfere with tumour repair following radiation-induced damage
Silymarin’s immunomodulatory effects may enhance antitumor immune responses following radiation-induced antigen release
Preclinical models in other cancers show silymarin reduces radiation-induced fibrosis and tissue damage via TGF-β/Smad pathway inhibition
Clinical trials evaluating topical or oral silymarin during colorectal radiotherapy are warranted given its safety profile and mechanistic plausibility
Practical Interpretation for Patients
Silymarin is not a treatment for colorectal cancer, but research suggests it may offer supportive benefits as an adjunct:
It may suppress tumour proliferation and induce apoptosis through modulation of Bax/Bcl-2, caspase cascades, and immunogenic cell death markers
It shows potential to inhibit the Wnt/β-catenin pathway, a key driver in colorectal carcinogenesis, particularly in mutant APC contexts
It appears to target cancer stem cells, which are implicated in recurrence and therapy resistance
It may enhance chemotherapy efficacy (particularly with doxorubicin) while reducing hepatotoxicity and other organ toxicities
It has demonstrated favourable safety profiles in preclinical and clinical studies, with no significant liver or kidney toxicity observed at therapeutic doses
Any consideration should involve discussion with oncology professionals regarding timing (e.g., avoiding high-dose antioxidants during radiotherapy if pro-oxidant tumour effects are desired) and formulation (standardised extracts vs. nanoparticles)
PD-L1 suppression and immune activation
A notable 2024 finding showed that silymarin suppressed both proliferation and PD-L1 expression in colorectal cancer cells while increasing inflammatory CD8+ T-cell populations in tumour-bearing mice (good news). This gives Milk Thistle / Silymarin real immuno-oncology interest in this cancer type.
References for Silymarin in Colorectal Cancer
Silymarin suppresses proliferation and PD-L1 expression in colorectal cancer cells and increases inflammatory CD8+ cells in tumour-bearing mice (2024): https://pubmed.ncbi.nlm.nih.gov/39048076/
Silymarin suppresses the proliferation of colorectal cancer cells (2024): https://www.sciencedirect.com/science/article/abs/pii/S2210740124001463
Silymarin-Loaded Tin(IV) Nanoparticles Exhibit Enhanced Bioavailability and Antiproliferative Effects on Colorectal Cancer Cells (2023): https://pubs.acs.org/doi/10.1021/acsabm.3c00434
Curcumin sensitizes silymarin to exert synergistic anti-proliferative effects in colorectal cancer cells (2016): https://www.jcancer.org/v07p1250.htm
Therapeutic potential and mechanistic insights of silibinin targeting colorectal cancer-associated fibroblasts (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12000085/
Silibinin suppresses growth of human colorectal carcinoma cells harboring mutant APC gene via targeting beta-catenin signaling (2010): https://pubmed.ncbi.nlm.nih.gov/20454513/
Silibinin and colorectal cancer chemoprevention - PMC - NIH (2015): https://pmc.ncbi.nlm.nih.gov/articles/PMC5138577/
Dietary silymarin supplementation enhances chemotherapy efficacy and reduces adverse effects (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC11972028/
Therapeutic potential and mechanistic insights of silibinin targeting colorectal cancer-associated fibroblasts (2025): https://pubmed.ncbi.nlm.nih.gov/40242441
Colorectal cancer stem cells crosstalk in tumor immune microenvironment (2025): https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1714954/full
Silymarin plus doxorubicin exerts anti-hepatocellular effects via downregulation of TCF4 and β-catenin in human colorectal cancer (2025): https://www.sciencedirect.com/science/article/pii/S0890850825000155
Inhibition of Wnt Signalling by Silymarin in Human Colorectal Cancer Cells (2015): http://www.biomolther.org/journal/DOIx.php?id=10.4062%2Fbiomolther.2015.154
Trusted product: MCS Formulas Milk Thistle Silymarin 500mg
500 mg Milk Thistle extract per capsule, standardised to a minimum of 80% silymarin.
https://www.mcsformulas.com/vitamins-supplements/milk-thistle-silymarin/
Use the code abbey5 at checkout to save 5% and help support the free Healing Cancer Study Support resources.
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.